SCYNEXIS INC

SCYNEXIS, Inc. (Nasdaq: SCYX) is a biopharmaceutical company dedicated to advancing innovative solutions for severe rare diseases, with a primary focus on developing novel antifungal therapies to address difficult-to-treat and drug-resistant fungal infections. The company's website is www.scynexis.com.

The company's core business centers on its proprietary antifungal platform called "fungerps," a novel class of antifungal agents known as triterpenoids that function as structurally distinct glucan synthase inhibitors. These compounds demonstrate broad-spectrum activity against numerous human fungal pathogens, including Candida and Aspergillus genera, multidrug-resistant strains, and species such as Pneumocystis, Coccidioides, Histoplasma, Blastomyces, and most common mucorales species.

Ibrexafungerp, the first representative of the fungerp class, received FDA approval as BREXAFEMME for treating vulvovaginal candidiasis and reducing recurrent vulvovaginal candidiasis. This product was licensed to GlaxoSmithKline Intellectual Property (No.3) Limited in May 2023, representing a significant commercialization partnership. The company retains potential milestone payments and royalties from GSK based on BREXAFEMME sales for its approved indications.

SCY-247, a second-generation fungerp candidate, represents the company's lead development program. The FDA has granted this oral formulation Qualified Infectious Disease Product status and Fast Track designation, which would provide regulatory exclusivity of at least ten years following commercial approval. The company recently completed single and multiple ascending dose portions of a Phase 1 study in healthy subjects, with plans to initiate Phase 1 studies of the intravenous formulation in early 2026 and advance to Phase 2 clinical proof-of-concept studies in invasive candidiasis during 2026.

Beyond its internal pipeline, SCYNEXIS maintains licensing agreements with multiple partners including Hansoh for Greater China commercialization rights, R-Pharm for Russian Federation and select other markets, and Waterstone for SCY-635 viral disease applications. The company does not own or operate manufacturing facilities and relies on third-party contract manufacturers for drug substance and product manufacturing. Additional compounds from the fungerp platform remain in earlier development stages targeting significant unmet medical needs in infectious disease treatment.